Abstract: The centrally induced gastroprotective effect of neuropeptides has been intensively studied. Besides many similarities, however, differences can also be observed in their gastroprotective actions. The gastroprotective dose-response curve proved to be either sigmoid, or bell-shaped. Additional gastrointestinal effects of neuropeptides can contribute to their mucosal protective effect. Part of the neuropeptides induce gastroprotection by peripheral administration as well. Besides vagal nerve the sympathetic nervous system may also be involved in conveying the central effect to the periphery. Better understanding of the complex mechanism of the maintenance of gastric mucosal integrity may result in the development of new strategy to enhance gastric mucosal resistance against injury. 
Introduction.
The peripheral mechanisms responsible for gastric mucosal integrity have been revealed in many aspects. Several compounds, mediators have been demonstrated to play a role in the maintenance of mucosal integrity, like bicarbonate, mucus, phospholipids, trefoil peptides, prostaglandins (PGs), sensory neuropeptides, nitric oxide (NO), hydrogen sulfide, heat shock proteins, hypoxia-inducible factor-1 or various growths factors (for reviews see e.g. [1-3,4**]). However, the role of the central nervous system (CNS) has also been raised in the regulation of gastric mucosal damage/protection. The dorsal vagal complex (DVC, including the dorsal motor nucleus of vagus (DMN), nucleus of the solitari tract (NTS) and area postrema) and the hypothamus have prominent role in the regulation of gastrointestinal functions and well defined interconnections between the neuroendocrine hypothalamus and the central autonomic system have been described [5] .
Lesion or electrical stimulation of different brain areas resulted in either development of gastric mucosal injury or stimulation of protective processes [6**]. However, most of the evidence on the involvement of CNS in regulation of gastric mucosal integrity came from pharmacological interventions. In the first experimental series mainly acid-dependent ulcer models were used, like stress-induced mucosal injury, which was inhibited by bombesin, neurotensin, β-endorphin, substance P or somatostatin injected into the cisterna magna (intracisternally, i.c.), or corticotropin-releasing factor (CRF) given into the amygdala or into the lateral brain ventricle (intracerebroventricularly, i.c.v.) . Other peptides, like amylin (i.c.v.), bombesin or different opioids (injected i.c.) have been demonstrated to be effective in another acid-dependent, indomethacin-ulcer model [6**,7-8].
A new chapter was opened when thyrotropin-releasing hormon (TRH), that plays a key role in the regulation of the autonomic nervous system, injected i.c. or into the DMN in low (0-5-1.5 ng), non-secretory dose was shown to inhibit the gastric mucosal damage against ethanol injury, which is an acid-independent ulcer model and widely used for the analysis of gastroprotective action [6**,9]. This finding initiated an intensive research, and as a result several neuropeptides were shown to be gastroprotective given centrally. For example, from the calcitonin family α-CGRP (i.c.), adrenomedullin (i.c.) and amylin (i.c.v.) were highly effective against mucosal injury induced by ethanol, while calcitonin (i. (Table 1 ). The differences in the effective dose range can be due to several reasons, such as different intrinsic activities, partial/full agonistic property, permeation of the peptides to their receptors, density of their receptors in the site of action (e.g. dorsal vagal complex) or interactions with other neuropeptides / mediators.
Dose-reponse relationships
The dose-reponse curves of neuropeptides proved to be partly sigmoid, partly bellshaped ( Figure 2 ). It has been recognized already 40 years ago, that increasing the dose of a peptide the effect, after reaching a platue, can decrease, disappear or even reverse. Common characteristic of the bell-shaped (also called inverted U-shaped or hormetic) dose-response relationships is that the reduced or reversed effect may be expected typically in 10-and 100-fold of the stimulatory (inhibitory) dose-range (though the range can also be much wider) (for reviews see [26, 27] [15] . In most cases the gastroprotective ranges varied between 10-and 100-fold, which is in agreement with the biphasic responses observed in other fields.
On the other hand, with other neuropeptides, such as ghrelin, opioids, amylin or nesfatin-1 the mucosal protective effect did not decline at higher doses, despite of the wide tested dose ranges [17*,21,23,30] .
Interestingly, however, ghrelin or amylin has biphasic effects on other gastrointestinal functions (gastric emptying, gastric acid secretion) [31, 32] . The phenomenon of bell-shaped or biphasic dose-response relationship of neuropeptides should be also considered in study designs both under experimental conditions and human trials.
Although the bell-shaped effect is rather commonly observed, the analysis of the underlying mechanism in most cases is lacking. In some cases it can be resulted from a mixed agonist/antagonist action mediated by different receptor populations. Khan et al. [33] for example reported that the biphasic effect of substance P on striatal dopamine outflow is determined by the balance between muscarinic M 1 (stimulatory) and M 2 (inhibitory) receptors.
Another possibility is that additional gastrointestinal effects, e.g. increased gastric acid secretion or altered gastric motility may counteract the mucosal protective action at higher doses. Moreover, interactions between neuropeptides may also modify the gastroprotective effect.
Additional gastrointestinal effects and interactions of neuropeptides
TRH in higher dose range than the gastroprotective one stimulates gastric acid secretion, gastric motor activity and aggravates experimentally induced gastric mucosal lesions [35] . In contrast, nociceptin (possessing a bell-shaped dose-response curve) exerts inhibitory effect on gastric acid secretion even in 10-50 times higher dose range than the gastroprotective one 
Gastroprotection initiated centrally or peripherally
Some of the neuropeptides are protective only after central administration, and given peripherally either lack of effect, or even aggravation of mucosal damage can be observed. 
Factors conveying the centrally inititated effect to the periphery
As mentioned above, vagally mediated gastroprotective effect has been demonstrated for the majority of neuropeptides. However, several data suggest that besides vagal nerve other mechanisms may also play a role in conveying the centrally initiated effect to the periphery. For example both adrenergic and cholinergic systems are likely to be involved in the gastroprotective effect of centrally injected ghrelin, since only parallel inhibition of both systems were able to abolish it [51] . Furthermore, the gastroprotective effect of angiotensin II injected into the paraventricular nucleus of the hypothalamus was not affected by subdiaphragmatic vagotomy or atropine, but was abolished by propranolol or disconnection of the nerves innervating the adrenal glands indicating the importance of the sympathetic-adrenal gland/beta-adrenoceptor pathway [52] . The gastroprotective effect of nociceptin was blocked by atropine, subdiaphragmatic vagotomy and bretylium, suggesting that both vagal cholinergic and sympathetic pathways mediate the central activity of this peptide [53] . 
Conclusion
Increasing number of evidence suggests the crucial role of neuropeptides in gastric mucosal integrity. However, several questions remained to be answered to elucidate their precise role in this process. For example, further studies are needed to clarify: whether changes of endogenous level of neuropeptides may result in gastroprotective (or damaging) effect; the precise anatomical background (brain areas, projections) involved in regulation of mucosal integrity; relevance of neuropeptide-interactions in gastroprotection; how the effective gastroprotective dose range relates to other actions of the neuropeptides; and the importance of the blood-brain and brain-blood transport of neuropeptides. It may be speculated that since some peptides using transporters can enter the brain following peripheral administration (46**), they may induce gastroprotective effect by central mechanism. Vice versa, the brain-to-blood transport might result also peripheral effect following central adminsitration of the peptides. Peripheral administration of peptides or peptide analogues which can cross the bood-brain barrier, or agents that may modify the endogenous level of gastroprotective neuropeptides might represent new therapeutic possibilities against gastric mucosal injury. Moreover, better understanding of the complex (and virtually redundant) mechanism of the maintenance of gastric mucosal integrity may serve as a basis for the development of new strategies to enhance gastric mucosal resistance against injury.
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